Qx Therapeutics Inc. has received FDA authorization of “Study May Proceed” with a Phase 2 Clinical Trial of QXT-101 for the prevention and treatment of PGD in lung transplant recipients.”
Passionate about innovation? JOIN US FOR A BLAVATNIK FELLOWSHIP INFOSESSION 02/16/2022 12:00PM—1:00PM
Leading (Yale) Bioscience Entrepreneurs Sign Leases at New 113,000 SF Elm City Bioscience Center in New Haven
OCR welcomes new Managing Director - Geballe Named Senior Associate Provost for Entrepreneurship & Innovation
Hongyu Zhao, PhD Ira V. Hiscock Professor of Biostatistics, Professor of Genetics and Professor of Statistics and Data Science; Affiliated Faculty, Yale Institute for Global Health
